Changes in Hong Kong stocks | Nuochengjianhua (09969) is now up more than 5%, ICP-488 phase II trial results are positive, institutions are optimistic about the TYK2 psoriasis treatment market

The Zhitong Finance App learned that Nuocheng Jianhua (09969) is now up more than 5%. As of press release, it has risen 5.28% to HK$6.78, with a turnover of HK$140,189,000.

According to the news, Nuochengjianhua held an investor conference on October 10. The positive results of the ICP-488 (TYK2) Phase 2 clinical trial of patients with moderate to severe plaque psoriasis were treated by the branch office. The study reached the main critical point of PASI 75 at week 12, and there were significant statistical differences between the daily doses of 6 mg and 9 mg, and other efficacy indicators also showed good prospects.

UBS released a research report saying it believes the results of the company's Phase 2 study can support Phase 3. The company has been actively seeking potential global partners for this asset. Guotai Jun An pointed out that currently there are only 2 Tyk2 inhibitors on the market worldwide (BMS for psoriasis & Astellas for rheumatoid arthritis). Nuochengjianhua's ICP-488 psoriatic disease is leading the domestic progress, showing BIC potential, and is optimistic about the TYK2 psoriatic treatment market.